127 related articles for article (PubMed ID: 30582799)
1. DM1 Loaded Ultrasmall Gold Nanoparticles Display Significant Efficacy and Improved Tolerability in Murine Models of Hepatocellular Carcinoma.
Hale SJM; Perrins RD; Garcı A CE; Pace A; Peral U; Patel KR; Robinson A; Williams P; Ding Y; Saito G; Rodriguez MÁ; Perera I; Barrientos A; Conlon K; Damment S; Porter J; Coulter T
Bioconjug Chem; 2019 Mar; 30(3):703-713. PubMed ID: 30582799
[TBL] [Abstract][Full Text] [Related]
2. A highly potent maytansinoid analogue and its use as a cytotoxic therapeutic agent in gold nanoparticles for the treatment of hepatocellular carcinoma.
Porter J; Ding Y; Hale SJM; Perrins RD; Robinson A; Mazanetz MP; Wu Y; Ma Y; Conlon K; Coulter T
Bioorg Med Chem Lett; 2020 Dec; 30(24):127634. PubMed ID: 33148516
[TBL] [Abstract][Full Text] [Related]
3. Revival of a potent therapeutic maytansinoid agent using a strategy that combines covalent drug conjugation with sequential nanoparticle assembly.
Xie K; Song S; Zhou L; Wan J; Qiao Y; Wang M; Xie H; Zhou L; Zheng S; Wang H
Int J Pharm; 2019 Feb; 556():159-171. PubMed ID: 30553007
[TBL] [Abstract][Full Text] [Related]
4. Enhanced immunotherapy of SM5-1 in hepatocellular carcinoma by conjugating with gold nanoparticles and its in vivo bioluminescence tomographic evaluation.
Ma X; Hui H; Jin Y; Dong D; Liang X; Yang X; Tan K; Dai Z; Cheng Z; Tian J
Biomaterials; 2016 May; 87():46-56. PubMed ID: 26897539
[TBL] [Abstract][Full Text] [Related]
5. Zein nanoparticles as nontoxic delivery system for maytansine in the treatment of non-small cell lung cancer.
Yu X; Wu H; Hu H; Dong Z; Dang Y; Qi Q; Wang Y; Du S; Lu Y
Drug Deliv; 2020 Dec; 27(1):100-109. PubMed ID: 31870183
[No Abstract] [Full Text] [Related]
6. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice.
Zhao X; Chen Q; Li Y; Tang H; Liu W; Yang X
Eur J Pharm Biopharm; 2015 Jun; 93():27-36. PubMed ID: 25770771
[TBL] [Abstract][Full Text] [Related]
7. Gold nanoparticles delivered miR-375 for treatment of hepatocellular carcinoma.
Xue HY; Liu Y; Liao JZ; Lin JS; Li B; Yuan WG; Lee RJ; Li L; Xu CR; He XX
Oncotarget; 2016 Dec; 7(52):86675-86686. PubMed ID: 27880727
[TBL] [Abstract][Full Text] [Related]
8. Honokiol nanoparticles based on epigallocatechin gallate functionalized chitin to enhance therapeutic effects against liver cancer.
Tang P; Sun Q; Yang H; Tang B; Pu H; Li H
Int J Pharm; 2018 Jul; 545(1-2):74-83. PubMed ID: 29715531
[TBL] [Abstract][Full Text] [Related]
9. Fabrication, optimization, and characterization of umbelliferone β-D-galactopyranoside-loaded PLGA nanoparticles in treatment of hepatocellular carcinoma: in vitro and in vivo studies.
Kumar V; Bhatt PC; Rahman M; Kaithwas G; Choudhry H; Al-Abbasi FA; Anwar F; Verma A
Int J Nanomedicine; 2017; 12():6747-6758. PubMed ID: 28932118
[TBL] [Abstract][Full Text] [Related]
10. Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer.
Feng L; Yao HP; Zhou YQ; Zhou J; Zhang R; Wang MH
J Exp Clin Cancer Res; 2016 Apr; 35():70. PubMed ID: 27102688
[TBL] [Abstract][Full Text] [Related]
11. Glutathione-Sensitive Hyaluronic Acid-SS-Mertansine Prodrug with a High Drug Content: Facile Synthesis and Targeted Breast Tumor Therapy.
Zhong P; Zhang J; Deng C; Cheng R; Meng F; Zhong Z
Biomacromolecules; 2016 Nov; 17(11):3602-3608. PubMed ID: 27723970
[TBL] [Abstract][Full Text] [Related]
12. Affibody-derived drug conjugates: Potent cytotoxic molecules for treatment of HER2 over-expressing tumors.
Altai M; Liu H; Ding H; Mitran B; Edqvist PH; Tolmachev V; Orlova A; Gräslund T
J Control Release; 2018 Oct; 288():84-95. PubMed ID: 30172673
[TBL] [Abstract][Full Text] [Related]
13. Enhanced antitumor efficacy, biodistribution and penetration of docetaxel-loaded biodegradable nanoparticles.
Liu Q; Li R; Zhu Z; Qian X; Guan W; Yu L; Yang M; Jiang X; Liu B
Int J Pharm; 2012 Jul; 430(1-2):350-8. PubMed ID: 22525076
[TBL] [Abstract][Full Text] [Related]
14. Preclinical Efficacy and Safety Assessment of an Antibody-Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma.
Nguyen M; Miyakawa S; Kato J; Mori T; Arai T; Armanini M; Gelmon K; Yerushalmi R; Leung S; Gao D; Landes G; Haak-Frendscho M; Elias K; Simmons AD
Clin Cancer Res; 2015 Dec; 21(24):5552-62. PubMed ID: 26240273
[TBL] [Abstract][Full Text] [Related]
15. Enhancing anti-tumor efficiency in hepatocellular carcinoma through the autophagy inhibition by miR-375/sorafenib in lipid-coated calcium carbonate nanoparticles.
Zhao P; Li M; Wang Y; Chen Y; He C; Zhang X; Yang T; Lu Y; You J; Lee RJ; Xiang G
Acta Biomater; 2018 May; 72():248-255. PubMed ID: 29555460
[TBL] [Abstract][Full Text] [Related]
16. EpCAM aptamer-functionalized polydopamine-coated mesoporous silica nanoparticles loaded with DM1 for targeted therapy in colorectal cancer.
Li Y; Duo Y; Bao S; He L; Ling K; Luo J; Zhang Y; Huang H; Zhang H; Yu X
Int J Nanomedicine; 2017; 12():6239-6257. PubMed ID: 28894364
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin and curcumin co-loaded nano-liposomes for the treatment of hepatocellular carcinoma.
Cheng Y; Zhao P; Wu S; Yang T; Chen Y; Zhang X; He C; Zheng C; Li K; Ma X; Xiang G
Int J Pharm; 2018 Jul; 545(1-2):261-273. PubMed ID: 29730175
[TBL] [Abstract][Full Text] [Related]
18. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
Zheng N; Liu W; Li B; Nie H; Liu J; Cheng Y; Wang J; Dong H; Jia L
J Exp Clin Cancer Res; 2019 May; 38(1):232. PubMed ID: 31151472
[TBL] [Abstract][Full Text] [Related]
19. Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma.
Tang X; Chen L; Li A; Cai S; Zhang Y; Liu X; Jiang Z; Liu X; Liang Y; Ma D
Drug Deliv; 2018 Nov; 25(1):1484-1494. PubMed ID: 29916268
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells.
Tassone P; Gozzini A; Goldmacher V; Shammas MA; Whiteman KR; Carrasco DR; Li C; Allam CK; Venuta S; Anderson KC; Munshi NC
Cancer Res; 2004 Jul; 64(13):4629-36. PubMed ID: 15231675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
